Biofrontera reports record preliminary Q4 2025 revenue of $17.0-17.5M, up ~35-39% YoY

Biofrontera Inc.

2025-FY EPS reported -$1.04 revenue$41,705,000

Q4 2025 preliminary revenue $17.0-17.5M, highest quarterly revenue in history, YoY growth 35-39%.
Full year 2025 preliminary revenue $41.5-42.0M, YoY growth 11-13%.
CEO cites strong Ameluz sales execution and December pricing adjustment driving record quarter.
Recent transaction with Biofrontera AG expected to improve gross margin profile and strengthen finances.
Final Q4 and full year 2025 results to be reported in March 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.